Physician profile
Mayank Mathur
NPI 1750591087
$9,660.78
in general payments reported to CMS, 2019-2025
69 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $430 · 2021: $1,073 · 2022: $1,470 · 2023: $1,647 · 2024: $1,724 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,993.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,139.89 | 2019-2025 | |
| Biogen, INC. | $948.50 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Ucb, INC. | $728.81 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Emd Serono, INC. | $464.86 | 2019-2025 | Mavenclad |
| Pfizer INC. | $457.03 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $447.83 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $422.53 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Alexion Pharmaceuticals, INC. | $323.71 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $250.52 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| W. L. Gore & Associates, INC. | $238.09 | 2020-2025 | Gore Cardioform Septal Occluder |
| Novartis Pharmaceuticals Corporation | $224.95 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $216.86 | 2023-2025 | Ztlido |
| Celgene Corporation | $182.23 | 2021-2024 | Zeposia |
| Avanir Pharmaceuticals, INC. | $181.71 | 2019-2022 | |
| Genentech USA, INC. | $172.39 | 2019-2025 | Ocrevus Zunovo |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayank Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.